TransCode Therapeutics, Inc.
RNAZ
$6.73
-$0.27-3.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -106.87% | -81.78% | -37.39% | -49.59% | 9.66% |
| Total Depreciation and Amortization | -78.65% | -65.17% | -44.09% | -20.39% | 3.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 364.04% | 540.95% | 471.34% | 1,072.64% | 212.06% |
| Change in Net Operating Assets | 104.44% | 118.59% | -1,140.10% | 106.24% | 67.51% |
| Cash from Operations | -46.34% | 8.41% | 7.10% | 28.59% | 26.22% |
| Capital Expenditure | 69.27% | 97.65% | -3.08% | 32.08% | 38.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 79.82% | 97.65% | -3.08% | 32.08% | 38.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -46.01% | 54.77% | 21.70% | -7.91% | 3.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 92.20% | 50.34% | 20.62% | -7.91% | 3.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 294.37% | 117.22% | 1,945.87% | 102.23% | 238.29% |